Pfizer Inc. — HYMPAVZI (marstacimab) · Hemophilia A or B.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (12/22/25) through T+5. Run-up high $28.55 on 4/3/26, low $24.88 on 12/31/25 (T-120 to T-1). FDA decision 6/8/26. Historical price action, not a forecast.